Insider · CIK 0001569926
Sean P. Nolan
Files at VTR (Ventas, Inc.), TSHA (Taysha Gene Therapies, Inc.). First filing Jan 27, 2026, latest Jan 27, 2026.
In brief
Sean P. Nolan files SEC Form 4 as director and CEO at TSHA (Taysha Gene Therapies, Inc.), and also at VTR (Ventas, Inc.). Since Jan 27, 2026, Sean P. Nolan has reported 0 open-market buys worth $0 and 1 open-market sell worth $840k, the latest filed on Jan 27, 2026.
A track record needs three past buys with six months of prices behind them; Sean P. Nolan has 0, so none is measured yet.
The newest scored trade: sold $840k of TSHA on Jan 23, 2026, filed Jan 27, 2026, scored 63 (notable). In the last 12 months: 0 buys worth $0 and 1 sell worth $840k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TSHA: Taysha Gene Therapies, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 63Notable | Taysha Gene Therapies, Inc. | $840k 178,101 shares | -6% | +312% from low-21% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 23, 2026 | TSHA TAYSHA GENE THERAPIES, INC. | 168,078 0.06% of outstanding | $856k | Jan 23, 2026 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 13, 2026 | VTR Ventas, Inc. | AGrant or award Common Stock | +2,047 | $90.35 | $185k | 26,181 | May 15, 2026 |
| Jan 23, 2026 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -136,789 | $4.75 | $650k | 2,949,569 | Jan 27, 2026 |
| Jan 26, 2026 | TSHA Taysha Gene Therapies, Inc. | SOpen-market sale Common Stock | -41,312 | $4.61 | $190k | 2,908,257 | Jan 27, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Common Stock | +1,008,000 | $0.00 | $0 | 3,086,358 | Jan 14, 2026 |
| Jan 12, 2026 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +648,000 | $0.00 | $0 | 648,000 | Jan 14, 2026 |
| May 13, 2025 | VTR Ventas, Inc. | AGrant or award Common Stock | +2,882 | $64.18 | $185k | 24,134 | May 15, 2025 |
| Jan 2, 2024 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Common Stock | +1,184,688 | $0.00 | $0 | 1,185,858 | Jan 4, 2024 |
| Jan 2, 2024 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +1,184,688 | $0.00 | $0 | 1,184,688 | Jan 4, 2024 |
| Dec 14, 2023 | TSHA Taysha Gene Therapies, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +466,550 | $0.00 | $0 | 466,550 | Dec 18, 2023 |
Questions about Sean P. Nolan
Answered from the filings on this page, as of the latest one.
Is Sean P. Nolan buying or selling?
In the last 12 months Sean P. Nolan reported 0 open-market buys worth $0 and 1 open-market sell worth $840k on SEC Form 4; the latest was sold $840k of TSHA on Jan 23, 2026. Grants, option exercises and tax withholding are not counted.
How did Sean P. Nolan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sean P. Nolan has 0.
Where does Sean P. Nolan file Form 4?
Sean P. Nolan has filed Form 4 at TSHA (Taysha Gene Therapies, Inc.) as Chief Executive Officer; VTR (Ventas, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.